Amgen’s $28 billion Horizon buyout is the latest deal driven by patent cliff fears
The year’s largest acquisition sees several IP-backed rare disease treatments change hands
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.